Across TCGA pan-cancer cohorts, PPP1R36 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PPP1R36 data layer compared with 27 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher PPP1R36 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PPP1R36 expression acts as an unfavorable survival marker.
COAD, ESCA, and PRAD are the cancer types where PPP1R36 Mutation most reproducibly stratifies survival.